Why has NICE said this?
Aflibercept does not provide enough benefit to patients compared with current treatment to justify its additional cost and did not qualify for special consideration, so it was not recommended.
NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life.